395 related articles for article (PubMed ID: 33357454)
21. p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S; Tchounwou PB
J Cell Mol Med; 2022 Sep; 26(17):4727-4739. PubMed ID: 35946055
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53.
Akay C; Gazitt Y
Cell Cycle; 2003; 2(4):358-68. PubMed ID: 12851490
[TBL] [Abstract][Full Text] [Related]
23. Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.
Feng C; Gong R; Zheng Q; Yan G; He M; Lei H; Li X; Zhang L; Xu Z; Liu S; Yu M; Ma T; Gao M; Bamba D; Idiiatullina E; Zagidullin N; Pavlov V; Xu C; Yuan Y; Yang L
Int J Biol Sci; 2019; 15(2):386-394. PubMed ID: 30745828
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
25. Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide.
Wahiduzzaman M; Ota A; Hosokawa Y
Curr Cancer Drug Targets; 2020; 20(2):115-129. PubMed ID: 31736446
[TBL] [Abstract][Full Text] [Related]
26. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D
Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells.
Ding X; Chi J; Yang X; Hao J; Liu C; Zhu C; Wang X; Liu X; Niu Y; Ji W; Chen D; Wu X
Leuk Lymphoma; 2017 Oct; 58(10):2439-2451. PubMed ID: 28278714
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Liu Q; Hilsenbeck S; Gazitt Y
Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
[TBL] [Abstract][Full Text] [Related]
29. In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment.
da Rosa FC; Buque Pardinho R; Schultz Moreira ME; de Souza LGT; de Moraes Flores ÉM; Mortari SR; Dressler VL
Leuk Res; 2019 Jan; 76():11-14. PubMed ID: 30472478
[TBL] [Abstract][Full Text] [Related]
30. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
31. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
Liu DM; Zhang XD; Yang L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Kircelli F; Akay C; Gazitt Y
Int J Oncol; 2007 Apr; 30(4):993-1001. PubMed ID: 17332940
[TBL] [Abstract][Full Text] [Related]
33. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
34. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V
Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602
[TBL] [Abstract][Full Text] [Related]
35. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
37. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
[TBL] [Abstract][Full Text] [Related]
39. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
Alfonso V; Iaccarino L; Ottone T; Cicconi L; Lavorgna S; Divona M; Cairoli R; Cristiano A; Ciardi C; Travaglini S; Falconi G; Hasan SK; Venditti A; Arcese W; Voso MT; Lo-Coco F
Leukemia; 2019 Jun; 33(6):1527-1530. PubMed ID: 30651632
[No Abstract] [Full Text] [Related]
40. Biotransformation of arsenic and toxicological implication of arsenic metabolites.
Hirano S
Arch Toxicol; 2020 Aug; 94(8):2587-2601. PubMed ID: 32435915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
